• español
  • English
  • français
  • Deutsch
  • português (Brasil)
  • italiano
    • español
    • English
    • français
    • Deutsch
    • português (Brasil)
    • italiano
    • español
    • English
    • français
    • Deutsch
    • português (Brasil)
    • italiano
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Navegar

    Todo o repositórioComunidadesPor data do documentoAutoresAssuntosTítulos

    Minha conta

    Entrar

    Estatística

    Ver as estatísticas de uso

    Compartir

    Ver item 
    •   Página inicial
    • PRODUÇÃO CIENTÍFICA
    • Grupos de Investigación
    • Grupo de Investigación en Virología Clínica, Diagnóstica y Epidemiológica
    • GIV - Artículos de Revista
    • Ver item
    •   Página inicial
    • PRODUÇÃO CIENTÍFICA
    • Grupos de Investigación
    • Grupo de Investigación en Virología Clínica, Diagnóstica y Epidemiológica
    • GIV - Artículos de Revista
    • Ver item
    • español
    • English
    • français
    • Deutsch
    • português (Brasil)
    • italiano

    Exportar

    RISMendeleyRefworksZotero
    • edm
    • marc
    • xoai
    • qdc
    • ore
    • ese
    • dim
    • uketd_dc
    • oai_dc
    • etdms
    • rdf
    • mods
    • mets
    • didl
    • premis

    Citas

    Por favor, use este identificador para citar o enlazar este ítem:http://uvadoc.uva.es/handle/10324/44628

    Título
    Cell culture-derived flu vaccine: Present and future
    Autor
    Pérez Rubio, Alberto
    Eiros Bouza, José MaríaAutoridad UVA Orcid
    Año del Documento
    2018
    Editorial
    Taylor & Francis
    Descripción
    Producción Científica
    Documento Fuente
    Human Vaccines & Immunotherapeutics, 2018, vol. 14, n. 8, p. 1874-1882
    Resumo
    The benefit of influenza vaccines is difficult to estimate due to the complexity of accurately assessing the burden of influenza. To improve the efficacy of influenza vaccines, vaccine manufacturers have developed quadrivalent influenza vaccine (QIV) formulations for seasonal vaccination by including both influenza B lineages. Three parallel approaches for producing influenza vaccines are attracting the interest of many vaccine manufacturing companies. The first and oldest is the conventional egg-derived influenza vaccine, which is used by the current licensed influenza vaccines. The second approach is a cell culture-derived influenza vaccine, and the third and most recent is synthetic vaccines. Here, we analyze the difficulties with vaccines production in eggs and compare this to cell culture-derived influenza vaccines and discuss the future of cell culture-derived QIVs.Keywords: Influenza vaccine, cell culture-derived, quadrivalent.
    Materias Unesco
    32 Ciencias Médicas
    Palabras Clave
    Vacuna
    Influenza
    ISSN
    2164-5515
    Revisión por pares
    SI
    DOI
    10.1080/21645515.2018.1460297
    Version del Editor
    https://www.tandfonline.com/doi/full/10.1080/21645515.2018.1460297
    Propietario de los Derechos
    © Taylor & Francis
    Idioma
    eng
    URI
    http://uvadoc.uva.es/handle/10324/44628
    Tipo de versión
    info:eu-repo/semantics/publishedVersion
    Derechos
    openAccess
    Aparece en las colecciones
    • GIV - Artículos de Revista [46]
    Mostrar registro completo
    Arquivos deste item
    Nombre:
    Cell-culture-derived-flu-vaccin.pdf
    Tamaño:
    641.7Kb
    Formato:
    Adobe PDF
    Thumbnail
    Visualizar/Abrir
    Attribution-NonCommercial-NoDerivatives 4.0 InternacionalExceto quando indicado o contrário, a licença deste item é descrito como Attribution-NonCommercial-NoDerivatives 4.0 Internacional

    Universidad de Valladolid

    Powered by MIT's. DSpace software, Version 5.10